FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York When will the FDA reclassify BPC 157 to Category 1 Octagon AI BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification